RGEN - Repligen Non-GAAP EPS of $0.92 beats by $0.20 revenue of $206.4M beats by $20.92M; updates FY22 guidance

Repligen press release (NASDAQ:RGEN): Q1 Non-GAAP EPS of $0.92 beats by $0.20. Revenue of $206.4M (+44.5% Y/Y) beats by $20.92M. GAAP gross margin was 60.1%, an increase of 190 bps; Adjusted (non-GAAP) gross margin was 60.4%, an increase of 100 bps. GAAP operating margin was 29.1%, an increase of 360 bps; Adjusted (non-GAAP) operating margin was 32.6%, an increase of 70 bps. Adjusted EBITDA for the first quarter of 2022 was $72.2 million, a year-over-year increase of $23.5 million, or 48%. FISCAL YEAR 2022 GUIDANCE:  Total revenue is expected to be in the range of $770-$800 million vs. consensus of $820.31M, a $30 million or approximate 4% reduction from our previous guidance of $800-$830 million. Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis, consistent with our previous guidance. Fully diluted GAAP EPS is expected to be in the range of $2.41-$2.49. Adjusted (non-GAAP) fully diluted

For further details see:

Repligen Non-GAAP EPS of $0.92 beats by $0.20, revenue of $206.4M beats by $20.92M; updates FY22 guidance